JP2022504607A5 - - Google Patents

Info

Publication number
JP2022504607A5
JP2022504607A5 JP2021519712A JP2021519712A JP2022504607A5 JP 2022504607 A5 JP2022504607 A5 JP 2022504607A5 JP 2021519712 A JP2021519712 A JP 2021519712A JP 2021519712 A JP2021519712 A JP 2021519712A JP 2022504607 A5 JP2022504607 A5 JP 2022504607A5
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
compound
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021519712A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022504607A (ja
JP7671244B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/055926 external-priority patent/WO2020077255A1/en
Publication of JP2022504607A publication Critical patent/JP2022504607A/ja
Publication of JP2022504607A5 publication Critical patent/JP2022504607A5/ja
Priority to JP2024020461A priority Critical patent/JP7899241B2/ja
Application granted granted Critical
Publication of JP7671244B2 publication Critical patent/JP7671244B2/ja
Priority to JP2026082628A priority patent/JP2026126430A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021519712A 2018-10-12 2019-10-11 Cns障害の処置において使用するための、10位において環式基で置換された神経刺激性ステロイド Active JP7671244B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024020461A JP7899241B2 (ja) 2018-10-12 2024-02-14 Cns障害の処置において使用するための、10位において環式基で置換された神経刺激性ステロイド
JP2026082628A JP2026126430A (ja) 2018-10-12 2026-05-15 Cns障害の処置において使用するための、10位において環式基で置換された神経刺激性ステロイド

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862745109P 2018-10-12 2018-10-12
US62/745,109 2018-10-12
PCT/US2019/055926 WO2020077255A1 (en) 2018-10-12 2019-10-11 Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024020461A Division JP7899241B2 (ja) 2018-10-12 2024-02-14 Cns障害の処置において使用するための、10位において環式基で置換された神経刺激性ステロイド

Publications (3)

Publication Number Publication Date
JP2022504607A JP2022504607A (ja) 2022-01-13
JP2022504607A5 true JP2022504607A5 (enExample) 2022-10-11
JP7671244B2 JP7671244B2 (ja) 2025-05-01

Family

ID=68425315

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021519712A Active JP7671244B2 (ja) 2018-10-12 2019-10-11 Cns障害の処置において使用するための、10位において環式基で置換された神経刺激性ステロイド
JP2024020461A Active JP7899241B2 (ja) 2018-10-12 2024-02-14 Cns障害の処置において使用するための、10位において環式基で置換された神経刺激性ステロイド
JP2026082628A Pending JP2026126430A (ja) 2018-10-12 2026-05-15 Cns障害の処置において使用するための、10位において環式基で置換された神経刺激性ステロイド

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024020461A Active JP7899241B2 (ja) 2018-10-12 2024-02-14 Cns障害の処置において使用するための、10位において環式基で置換された神経刺激性ステロイド
JP2026082628A Pending JP2026126430A (ja) 2018-10-12 2026-05-15 Cns障害の処置において使用するための、10位において環式基で置換された神経刺激性ステロイド

Country Status (14)

Country Link
US (2) US11634453B2 (enExample)
EP (2) EP3864022B1 (enExample)
JP (3) JP7671244B2 (enExample)
CN (2) CN113166193B (enExample)
AR (1) AR116695A1 (enExample)
AU (2) AU2019357040B2 (enExample)
BR (1) BR112021009428A2 (enExample)
CA (1) CA3115805A1 (enExample)
DK (1) DK3864022T3 (enExample)
ES (1) ES2966055T3 (enExample)
IL (1) IL282183A (enExample)
MX (2) MX2021004159A (enExample)
TW (2) TWI886813B (enExample)
WO (1) WO2020077255A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201606063RA (en) 2012-01-23 2016-09-29 Sage Therapeutics Inc Neuroactive steroid formulations and methods of treating cns disorders
RS62761B1 (sr) 2012-08-21 2022-01-31 Sage Therapeutics Inc Alopregnanolon za lečenje refraktornog epileptičkog statusa
SMT202100509T1 (it) 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
WO2018013613A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C17, c20, and c21 substituted neuroactive steroids and their methods of use
TW202604538A (zh) 2016-08-23 2026-02-01 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
US20200291059A1 (en) 2017-12-08 2020-09-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
AU2019357040B2 (en) 2018-10-12 2025-03-27 Sage Therapeutics, Inc. Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of CNS disorders

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
DK1038880T3 (da) * 1994-02-14 2008-03-03 Euro Celtique Sa Androstaner og pregnaner til allosterisk modulering af GABA-receptor
US5939545A (en) 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
BR9509764A (pt) 1994-11-23 1998-07-07 Cocensys Inc Série androstano e pregnano para modulação alostérica de receptor de gaba
PT837874E (pt) 1995-06-06 2005-03-31 Euro Celtique Sa Esteroides neuroactivos da serie androstano e pregnano
UA73736C2 (en) 1999-04-29 2005-09-15 Euro Celtic S A Method for alleviating or preventing insomnia and inducing anesthesia
DK2935307T3 (en) 2012-12-18 2018-07-30 Univ Washington NEUROACTIVE 19-ALKOXY-17-SUBSTITUTED STEROIDS USED IN METHODS OF TREATMENT
MY190408A (en) 2014-10-16 2022-04-21 Sage Therapeutics Inc Compositions and methods for treating cns disorders
CA3086299A1 (en) 2017-12-22 2019-06-27 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
EP3728285B1 (en) 2017-12-22 2026-04-08 Sage Therapeutics, LLC Compositions and methods for treating cns disorders
US12139508B2 (en) 2018-02-11 2024-11-12 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Steroid derivative regulators, method for preparing the same, and uses thereof
AU2019357040B2 (en) 2018-10-12 2025-03-27 Sage Therapeutics, Inc. Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of CNS disorders
CA3143545A1 (en) 2019-06-27 2020-12-30 Sage Therapeutics, Inc. Compounds for treating cns disorders
BR112021026447A2 (pt) * 2019-06-27 2022-04-12 Sage Therapeutics Inc Composições e métodos para tratamento de distúrbios de cns
AU2021238346A1 (en) 2020-03-18 2022-09-29 Sage Therapeutics, Inc. Neuroactive steroids and their methods of use
CN115768781A (zh) 2020-06-24 2023-03-07 萨奇治疗股份有限公司 3.α.-羟基,17.β.-C(O)-N-芳基取代的神经活性类固醇及其组合物

Similar Documents

Publication Publication Date Title
JP2022510683A5 (enExample)
JP2023531517A5 (enExample)
JP2022514385A5 (enExample)
JP2023537632A5 (enExample)
RU2405774C9 (ru) Гетероциклические ингибиторы аспартилпротеазы
RU2020123151A (ru) Антагонисты tlr7/8 и их применение
JP2023119042A5 (enExample)
JP2017531020A5 (enExample)
JP2019094345A5 (enExample)
JP2023518411A5 (enExample)
JP2022538301A5 (enExample)
JP2012526728A5 (enExample)
JP2018502891A5 (enExample)
JP2016517851A5 (enExample)
JP2019519587A5 (enExample)
JP2016510043A5 (enExample)
JP2012505836A5 (enExample)
JP2017525699A5 (enExample)
JP2022538300A5 (enExample)
JP2017533968A5 (enExample)
RU2012125372A (ru) Производные пиразола в качестве ингибиторов 11-бета-hsd1
JP2018505898A5 (enExample)
RU2005106846A (ru) Производные бензотиазола, характеризующиеся агонистической активностью к бета-2-адренорецепторам
JP2011521911A5 (enExample)
JP2003522763A (ja) ピペラジンアミド置換基を持つオキサゾリジノンチオアミド